by Raynovich Rod | Oct 29, 2013 | 2024 Rayno Tools and Diagnostics Portfolio, 2025 Rayno Biopharmaceuticals Portfolio
Dow, S&P and Biotech Sector Hit All Time Highs NASDAQ Still 1000+Pts Under 2000 High Levels After a 10% sell-off in early October many large cap biopharmaceutical and diagnostic stocks are at new highs with the major indices at or near their October highs. The...
by Raynovich Rod | Oct 25, 2013 | 2025 Rayno Biopharmaceuticals Portfolio
Biopharmaceutical stocks were somewhat mixed today yet we have some nice moves in our portfolio: Alexion (ALXN $125.26) up 7.34% on Q3 Results which showed a 36% increase in sales to $400M and Net Income (GAAP) of $93.8M up from $92.2M in the same quarter of 2012. The...
by Raynovich Rod | Oct 24, 2013 | 2024 Rayno Tools and Diagnostics Portfolio, 2025 Rayno Biopharmaceuticals Portfolio
Biotech Stocks Have Recovered From Early October Lows We have been traveling for two weeks and have not posted new content nor made portfolio changes. Despite a significant correction in the biotech sector in early October when major ETFs (IBB) and funds such as the...
by Raynovich Rod | Oct 9, 2013 | 2024 Rayno Tools and Diagnostics Portfolio, 2025 Rayno Biopharmaceuticals Portfolio
Expect to be back by 10/25 in the meantime see previous two posts. Biotech stocks remain choppy. Hold mode with 10% cash. Big action has moved to Internets and new media. See Raynoreport.com for market updates. ________________…………...
by Raynovich Rod | Oct 7, 2013 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Our Indicators Flash a Caution Signal Today No Change in Portfolio Picks If you are not at 10% cash in your biotechnology portfolio it is time to take profits or hedge your portfolio. If your biotech stock did not hit a new high last week you may want to sell it. Risk...
by Raynovich Rod | Oct 1, 2013 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Biotech Stocks Hit New Highs Unfazed By Shutdown Biopharmaceutical stocks continued their blazing Q3 run today buoyed by assumptions that demand for pharmaceuticals will increase with 55 million new potential patients from Obamacare and that healthcare stocks are less...
by Raynovich Rod | Sep 26, 2013 | 2025 Rayno Biopharmaceuticals Portfolio
Biotech Stocks Will Not Wait for Congress-Huge Rally Across the Board Analysts and Media are Piling On-Momentum Rules IBB up 1.75% XBI up 1.81% Rayno Biopharmaceuticals stocks are in a new leg up with large cap winners: Alexion (ALXN $115) up 2% Cubist (CBST $67.62)...
by Raynovich Rod | Aug 28, 2013 | 2024 Rayno Tools and Diagnostics Portfolio, 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals, Macro
But Uncertainty Clouds Intermediate Term Economic Outlook: Oil prices, Emerging Markets, Russia and the FED Concerns about another Middle East war and a spike in oil prices waned a bit today but many “undertoads” remain such as weak economic data, taper...
by Raynovich Rod | Aug 26, 2013 | 2024 Rayno Tools and Diagnostics Portfolio, 2025 Rayno Biopharmaceuticals Portfolio
Life science stocks resumed their upward trajectory today with major ETFs (FBT,IBB,XBI) up over 2% and a green screen for the sector. Mid-cap biopharma stocks are strong once again. The IBB hit an August low of $187 on August 19 after a high in early August near $201....
by Raynovich Rod | Aug 1, 2013 | 2024 Rayno Tools and Diagnostics Portfolio, 2025 Rayno Biopharmaceuticals Portfolio
Biotech ETF (IBB) Hits New High of $200-Mid Caps Get Turbo Boost Positive Economic Data Helps The life science sector roared ahead again today helped by a 1% move in NASDAQ now at YTD highs up 21%. With an earlier post last week we urged “staying the...
